CBLPath Receives Approval from New York State Department of Health for KRAS Mutation Analysis PCR Testing

Approval expands in-house molecular testing capabilities


RYE BROOK, N.Y. — CBLPath has received approval from the New York State Department of Health for KRAS mutation analysis PCR testing. KRAS mutations are frequently found in many types of cancer including colorectal and non-small cell lung carcinoma. These mutations are a strong predictor of a patient’s response to cancer therapies that target the epidermal growth factor receptor (EGFR) pathway such as erlotinib, gefitinib, cetuximab, and panitumumab.

“Our clients recognize CBLPath’s capabilities to provide not only definitive diagnostic information, but also prognostic and theranostic information,” said Dr. Carlos D. Urmacher, CBLPath’s Chief Medical Officer. “We are continuing to expand our test menu to include testing that addresses clinicians’ requirements in both the anatomic and molecular pathology markets.”

KRAS mutation testing is recommended by the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) before starting EGFR-targeted therapies in both metastatic colorectal cancer and advanced non-small cell lung cancer patients. KRAS mutations are also known to be present in other types of cancers including tumors of the pancreas, bile duct, ovary, appendix, breast and thyroid. While there are no recommendations for KRAS testing prior to beginning treatment for these cancers, these are all potential future applications.

“CBLPath prides itself on our unique leadership position in the industry convergence,” said David W. Bryant, CBLPath’s Chief Executive Officer. “As we continue to expand our molecular test menu over the coming months, we will be in the best position possible to help our clients deliver better medicine faster.”

CBLPath will be exhibiting at the United States and Canadian Academy of Pathology’s 100th Annual Meeting this week in San Antonio, TX. For more information as well as the complete test menu, please go to www.CBLPath.com

About CBLPath
CBLPath is a national specialty lab with a unique leadership position in the convergence of anatomic, molecular and digital pathology. Beginning from a clinical perspective, we harness molecular testing and digital pathology on an anatomic pathology foundation. CBLPath is committed to helping our clients deliver better medicine, faster. At our core are pathologists; excited about technology and innovation and its promise of helping patients. Through the Best Practice™ Partnership Program we help our pathologist-clients effectively compete against centralized reference laboratories, grow their Practice and remain independent — Keeping Medicine Local™. We provide our subspecialty physician clients comprehensive diagnostics and timely, accurate reports enabling the best patient care. For more about the company, please visit www.CBLPath.com.